Hundreds of people in England died before doctors diagnosed their tuberculosis

The Conversation examines how tuberculosis can be missed when its symptoms resemble other illnesses, using a fictional patient to illustrate diagnostic delays. It places England's experience in a global context and highlights the human and economic costs of late detection. The piece argues that early diagnosis is essential to curb transmission and reduce hardship for patients and their families.

• TB often goes undiagnosed because symptoms mimic other diseases such as emphysema or cancer.
• In England between 2010 and 2022, 574 people were diagnosed with TB only after death.
• Globally, TB remains the leading infectious killer, with 10.7 million cases and 1.23 million deaths in 2024.
• Factors like poverty, homelessness, and migration shape TB risk and access to care.

Overview

The Conversation article investigates how tuberculosis TB can be missed in clinical practice when its symptoms overlap with other conditions. It uses a fictional narrative to illustrate a patient named Dave who presents with a persistent cough, weight loss, fevers, night sweats, and an eventual death before TB is identified in the laboratory. The piece connects Dave's experience to larger, evidence based patterns showing that TB is frequently diagnosed late or not at all, with substantial consequences for patients, families and health systems.

England case study and posthumous diagnoses

Dave’s story shows how easily TB can be mistaken for smoking related diseases such as emphysema. A chest X ray reveals a white patch that raises cancer concerns, and a sputum sample is sent for testing. After several antibiotic courses and progressive deterioration, Dave dies before TB is identified. Although Dave is fictional, the article cites a 2026 study indicating that 574 people in England were diagnosed with TB only after death between 2010 and 2022, which equates to almost one person per week. These deaths represented 0.8% of all TB diagnoses, and nearly one in five deaths recorded among people with TB; the data do not confirm whether TB caused or contributed to each death.

TB in a global context

Beyond England, the article emphasizes that TB remains the world’s leading cause of death from a single infectious agent. In 2024, an estimated 10.7 million people developed TB and 1.23 million died. Global progress has rebounded from setbacks during the COVID pandemic but remains insufficient. The piece also notes that England’s 2024 TB incidence rate reached 9.4 per 100 000, reflecting a rise not seen since 1971 and highlighting that local progress depends on international improvements in prevention, diagnosis and treatment.

Determinants, disparities, and risks

The author discusses how poverty and deprivation closely relate to TB vulnerability, and how social determinants such as homelessness, imprisonment, substance use and limited access to healthcare can amplify exposure and hinder timely diagnosis. In England, the majority of diagnosed TB cases in 2024 involved people born outside the UK, illustrating how migration intersects with broader global inequalities in prevention and care. Even among UK born populations, TB remains associated with poverty and disparities in living conditions, which drive higher rates in deprived areas.

Delays, transmission, and costs

Delays between symptom onset and TB diagnosis allow ongoing transmission and worsen illness, often causing disruption to families and work and imposing substantial costs on patients and health services. The article cites a 72 day median delay for lung TB diagnosis in England in 2024, underscoring how much time can elapse before treatment begins. The piece argues that reducing diagnostic delays is essential to limit transmission and avoid avoidable financial hardship.

Implications and calls to action

To reduce missed TB cases, the article advocates for earlier diagnosis, improved access to care for at risk groups, and a broader recognition that TB is not solely a migration issue but a problem rooted in global inequalities. The author suggests that integrating clinical vigilance with social support systems, and deploying public health strategies that address housing, income and access to healthcare, are critical to move toward eliminating TB as a public health threat.

Conclusion

The story of Dave and the supporting data emphasize the need for proactive TB screening, better diagnostic pathways, and policies that address the social determinants of health. Early detection can prevent transmission, reduce suffering, and reduce the economic burden on individuals and health systems alike.